Articles published by HighTide Therapeutics Inc.
![](https://www.acnnewswire.com/images/company/HighTide2.jpg)
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
September 10, 2024
Via ACN Newswire
![](https://www.acnnewswire.com/images/company/HighTide2.jpg)
![](https://www.acnnewswire.com/images/company/HighTide2.jpg)
![](https://www.acnnewswire.com/images/company/HighTide2.jpg)
![](https://www.acnnewswire.com/images/company/HighTide2.jpg)
![](https://mms.businesswire.com/media/20220106005055/en/1319480/5/HIGHTIDE-EN_logo.jpg)
![](https://mms.businesswire.com/media/20211028005063/en/789669/5/logo-2E_BIG.jpg)
![](https://mms.businesswire.com/media/20210921005115/en/789669/5/logo-2E_BIG.jpg)
![](https://mms.businesswire.com/media/20210621005194/en/789669/5/logo-2E_BIG.jpg)
![](https://mms.businesswire.com/media/20210527005654/en/789669/5/logo-2E_BIG.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.